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Abstract
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Abstract Prostate cancer is the second leading cause of cancer deaths in the USA. The challenge in
managing castration-resistant prostate cancer (CRPC) stems not from the lack of therapeutic
options but from the limited duration of clinical and survival benefit offered by treatments in this
setting due to primary and acquired resistance. The remarkable molecular heterogeneity and tumor
adaptability in advanced prostate cancer necessitate optimization of such treatment strategies.
While the future of CRPC management will involve newer targeted therapies in deliberately
biomarker-selected patients, interventions using current approaches may exhibit improved clinical
benefit if employed in the context of optimal sequencing and combinations. This review outlines
our current understanding of mechanisms of therapeutic resistance in progression to and after the
development of castration resistance, highlighting targetable and reversible mechanisms of
resistance.

Keywords
Therapeutic resistance; Prostate cancer; Castration-resistant prostate cancer

Introduction
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In 2016, there will be over 180,000 new cases of prostate cancer in the USA alone,
accounting for over one in five new cancer diagnoses [1]. While it is also a leading cause of
cancer deaths, prostate cancer patients display a wide spectrum of clinical trajectories and
outcomes, where some achieve remission yet others rapidly develop lethal disease. Our
understanding of the use of systemic therapies to impair prostate tumor growth stems from
Huggins’ seminal discovery in 1941 on the therapeutic response of prostate cancer to
castration-induced androgen deprivation [2], groundbreaking work which led to his receipt
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of the Nobel Prize in 1966. Since then, while we have amassed more knowledge on the
intricacies of androgen signaling axis and the androgen receptor (AR), the treatment
paradigm for recurrent and advanced prostate cancer, as well as an adjuvant to localized
prostate cancer, remains dependent on androgen deprivation in the form of surgical or
medical castration, the latter via an approach known as androgen deprivation therapy (ADT)
[3]. Today, ADT is deployed for men with both metastatic and high-risk localized diseases
and is frequently utilized alongside other modalities.

Author Manuscript
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First-line ADT, most frequently administered in the form of luteinizing hormone-releasing
hormone (LHRH) agonists/antagonists with or without antiandrogens, suppresses prostatespecific antigen (PSA) levels in up to 90% of patients whose disease has spread beyond the
prostate [4]. While dramatic initial responses to ADT are not uncommon, these responses
are seldom sustained in the long term, with the median duration of response of up to
18months [5]. Virtually, all patients eventually progress to castration resistance, during
which biochemical and radiographic progression is observed despite castrate levels of serum
testosterone [6]. This key characteristic of continued tumor progression despite seemingly
“starved” androgen conditions led to the initial impression that castration-resistant prostate
cancer (CRPC) was a hormone-independent entity. The realization that CRPC remains
fueled by androgen signaling, albeit with an increased utility of nontraditional pathways and
alterations involving both the androgenic ligand (dihydrotestosterone (DHT)) and the AR
[7], led to newer AR-directed agents abiraterone and enzalutamide deployed in metastatic
CRPC (mCRPC) that are direct efficacious strategies targeting the continued dependence of
prostate cancer on androgens [8, 9]. These therapeutic manipulations, however, are also met
with resistance which remains an issue in the second-, third-, and fourth-line therapies—or
until the patient finally succumbs to his illness. Today, the median overall survival for
patients upon developing CRPC is in the range of 14–26 months [10].

Author Manuscript

Considering the augmentation of FDA-approved options for men with CRPC from only
docetaxel in 2004 to six [8, 9, 11–14] different therapies in 2016, there is great need to
understand the selective pressures that drive resistance to identify actionable targets that
prolong the duration of benefit offered by these treatments. In addition, questions
surrounding optimal treatment sequencing and combinations remain [15, 16] and are
currently being examined by both prospective and retrospective studies. Indeed, the issue of
resistance extends beyond patients developing refractory disease to continued therapy with
one agent to other agents in the form of cross-resistance occurring not only in the context of
drugs targeting the same pathway but also between drug classes [17–19]. With newer
treatments in the developmental pipeline, we are faced with a rapidly evolving clinical
landscape but a lagging understanding of how each treatment complements another and their
sequencing optimization platforms to maximize clinical efficacy. This review will examine
the known pathways of therapeutic resistance to systemic therapies, focusing on potentially
targetable resistance reversal strategies in advanced lethal CRPC.

Resistance to Androgen Ablation in Hormone-Sensitive Disease
Resistance to ADT is virtually inevitable but occurs after a unique timeline of therapy for
each patient after biochemical recurrence or diagnosis of advanced disease [20]. The clinical
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heterogeneity in progression to metastatic CRPC reflects the diversity of molecular
adaptations present in this setting. The deprivation of serum testosterone initially leads to
reduced levels of DHT, the primary mediator of AR signaling in prostate tissue. Upon
withdrawal of these ligands, the androgen-dependent tumor cells undergo dramatic
apoptosis, while a subset may maintain a dormant state [21]. Cancer stem cells have also
been appreciated in this setting in promoting progression to CRPC [22]. Eventually, a
population of such arrested cells is able to adapt to these states of low androgen, resuming
proliferation with progression manifesting in the form of rising PSA that may or may not be
coupled with osseous, soft tissue, or visceral metastases [23]. Progression to CRPC thus
represents a cumulation of resistance strategies deployed by cells against castration. These
critical adaptations involving the AR, ligand, as well as signaling regulators of the AR
mechanistic pathway are described in the following sections (and illustrated in Fig. 1).

Author Manuscript

AR Adaptations Towards Alternative Activation Mechanisms
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Among the strategies deployed by tumor cells to evade apoptosis induction by ADT, several
mechanisms fall under functional adaptations of AR actions. One of the earlier
breakthroughs in understanding the development of hormone-refractory disease came with
the observation of AR gene amplification [24, 25], detected in almost a quarter of CRPC
tissue specimens but virtually nonexistent in hormone-sensitive tissue [26]. In addition,
studies have shown that resistance to antiandrogens is consistently linked to upregulation of
AR expression [27], reflecting adaptations to increase sensitivity to low androgen (ligand)
levels in sustaining AR programs (Fig. 1(A)). Antiandrogens used in combined androgen
blockade in hormone-sensitive disease traditionally utilize bicalutamide, and less commonly
flutamide and nilutamide. An important observation in this setting was that 15–30% [28] of
tumors, upon becoming resistant to androgen blockade, would exhibit regressions after
discontinuation of therapy, a phenomenon clinically defined as antiandrogen withdrawal
syndrome (AWS) [29]. Now, we appreciate that certain AR mutations are well known to
reactivate AR signaling; the T877A mutation, for example, confers resistance to
hydroxyflutamide, the active form of flutamide [30]. W741C/L, another mutation of the AR
ligand binding domain (LBD), confers resistance to bicalutamide [31], both of which
illustrate the molecular basis of AWS. Additionally, the previously mentioned T877A
mutation coupled with another AR mutation L701H functionally confers a promiscuous
activation of the AR by glucocorticoids [32] (Fig. 1(B)). Comparisons between ARdependent target genes in androgen-independent and androgen-dependent cells reveal that
the AR-regulated transcriptional program is notably altered in castration-resistant disease,
especially in the context of cell cycle genes, some of which result in the inactivation of cell
cycle checkpoints [33].

Author Manuscript

AR activities can be stimulated by alternative signaling pathways, many of which play
significant roles in the development of other human malignancies [34]. The NF-κB
transcription factor signaling pathway has an established role in the progression to CRPC by
maintaining AR activity [35] and sustaining AR messenger RNA (mRNA) and protein
expression levels [36]. Further, its gene signature is sufficient in predicting prostate cancerspecific survival in clinical samples [37]. Other prominent survival signaling pathways
(bypassing AR-driven mechanisms) such as the PI3K/AKT pathway have also been
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examined in the context of progression to metastatic CRPC and established as contributors
to advanced metastatic disease [38]. The loss of phosphatase and tensin homolog deleted on
chromosome ten (PTEN), tumor suppressor, and negative regulator of this pathway is one of
the most frequent of molecular alterations in human prostate cancer. Indeed, PTEN loss
allows the promotion of growth independent of AR signaling, and given PTEN loss, the
development of castration resistance is intrinsic and not contingent on sustained AR activity
[39, 40]. Further, PTEN status at diagnosis is predictive of not only time to CRPC,
metastasis, and prostate cancer-specific survival but also response to ADT [41]. Finally,
growth factors including insulin-like growth factor 1 (IGF-1), keratinocyte growth factor
(KGF), and epidermal growth factor (EGF) have been shown to directly activate AR
independent of androgen [42]. A schematic representation of these pathways is depicted in
Fig. 1(C).

Author Manuscript

The AR is known to interact with a plethora of coactivators and corepressors (over 150)
[43], many of which play a role in the transition to castration-resistant disease. Co-activators
enhancing AR activity may functionally contribute to the AR’s heightened sensitivity to
alternative ligands in the absence of endogenous androgen [44]. For example, the coactivator
ARA70 can increase AR responsiveness to estradiol in prostate cancer cell lines [45] (Fig.
1(B)). FKBP51, another coactivator, stabilizes the HSP90-AR complex, enhancing the
ability of AR molecules to bind to androgen [46]. Finally, TRIM24 is a transcriptional
activator that has been shown to contribute to AR signaling under castrate androgen levels in
SPOP mutants and in CRPC [47] (Fig. 1(D)).
Ligand Synthesis Adaptations
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Castration-induced androgen withdrawal is known to deplete levels of circulating
testosterone by 90–95% and achieve castrate levels of serum testosterone (less than 20
ng/dL) in most patients [48]; however, there is evidence to suggest that intratumoral levels of
DHT in prostate tissue remain around 25% and could be as high as 40% of baseline prior to
therapy [49]. These levels of intratumoral androgen are sufficient to sustain androgen
signaling [50, 51] and can be accounted for in part by the contribution of androgen
precursors from the adrenal gland, namely dehydroepiandrosterone (DHEA) and DHEA-S,
its sulfated form. DHEA can be converted to DHT within the tumor via enzymes 3βhydroxysteroid dehydrogenase (3βHSD), steroid 5α-reductase (SRD5A), and 17βhydroxysteroid dehydrogenase (17βHSD) [52]. Emergence of prostate cancer cells to a
castration-resistant state involves the upregulation of various steroidogenic enzymes,
including HSD3B1, HSD3B2, HSD17B3, SRD5A1, and CYP17A1 for higher production of
intratumoral androgen [53, 54]. A gain of function mutation has been identified in 3βHSD,
conferring resistance to ubiquitination and degradation [55]. From a clinical standpoint, the
efficacy of cytochrome P450 17α-hydroxylase/17,20-lyase (CYP17), inhibiting agents
abiraterone and now the less commonly used ketoconazole, is reflective of the dependence
of CRPC on androgen metabolism [56]. Moreover, other nontraditional pathways for DHT
synthesis that can bypass biochemical synthesis of testosterone utilize precursors such as
acetic acid and progesterone [57]. A schematic representation of these pathways is shown in
Fig. 1(E).
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Impact of the Prostate Tumor Microenvironment: Can Epithelial-Mesenchymal Transition
Circumvent Apoptosis?
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While there have been significant molecular advances in genomic classification of human
cancer during disease progression to metastasis, our understanding of the biology of
individual tumors as an independent phenotypic entity is still profoundly limited; tumor
behavior and biological properties depend largely on cancer epithelial cells and the adjacent
stromal cells that comprise the tumor microenvironment [58]. It is in the very context of
shaping the tumor microenvironment landscape that epithelial-mesenchymal transition
(EMT) [59], a critical phenotypic process that confers invasive and migratory capacity to
localized primary tumor cells [60, 61] towards metastasis, has been implicated as a
contributing force (under androgenic control) to prostate cancer development and
progression. While androgens can induce EMT in prostate epithelial cells, low AR levels,
conditions reflective of ADT, seem crucial in sensitizing prostate cancer cells to androgenmediated EMT [62]. EMT induces tumor stem cell-like properties [63], contributing to
therapeutic resistance as well as evasion of apoptosis and immune surveillance [64]. While
EMT involves a variety of interactive signaling pathways, transforming growth factor β
(TGF-β) is recognized as the master orchestrator of this process, with hallmark
consequences of loss of the cell adhesion molecule E-cadherin [65] (Fig. 1(F)). Rapidly
growing evidence implicates EMT in human prostate cancer progression, with a significant
association with poorer outcomes and aggressive disease [66, 67]. Since ADT has been
shown to promote EMT, it may play an unorthodox role in fueling progression to lethal
prostate cancer. ADT can significantly alter the dynamics of the prostate tumor
microenvironment, affecting stromal, endothelial, and immune cells [68].

Author Manuscript
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Prostate cancer has a lower proliferative capacity compared to other solid tumors, and this
hallmark feature of growth kinetics renders apoptosis induction as a critical therapeutic
avenue for targeted therapies directed at the apoptotic signaling mechanisms responsible for
apoptosis evasion [69]. In the simplest terms, tumor progression results from an imbalance
in cell proliferation and death. While resisting cell death is a classic hallmark of neoplasms
[70], few compounds specifically targeting the apoptotic pathway have progressed in the
developmental pipeline to phase III clinical studies in prostate cancer [71]. AR as a critical
transcription factor in the regulation of prostate cell growth acts as a repressor for proapoptotic genes; initiation of ADT triggers apoptotic cascades in hormone-sensitive prostate
cancer cells and prostatic glandular epithelium [72]. In the subset of cells capable of evading
apoptosis, the cellular machinery to activate the cascade is retained but severely altered. In
the development of CRPC, molecular changes within prostate cancer cells may prevent the
transcription of genes involved in the programmed cell death in castrate conditions [73].
Further, overexpression of Bcl-2, a protagonist antiapoptotic molecule belonging to the
Bcl-2 family of proand antiapoptotic signaling effectors [74] (Fig. 1(G)), is associated with
prostate cancer progression and confers resistance to ADT [75]. Bcl-2 has long attracted
interest as a viable target in various tumors, most notably in the form of antisense
oligonucleotides and small molecule inhibitors [76].
Anoikis describes a related modality of cell death, whereby cells undergo apoptosis upon
detachment from the extracellular matrix (ECM), a process that must be evaded for tumor
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cells to spread [77]. This is an essential tactic deployed by tumor cells as both a means of
metastatic spread and therapeutic resistance. Tumor cells undergoing EMT are able to
circumvent anoikis through cellular reprogramming; pro-EMT molecules including but not
limited to transcriptional repressors SNAIL and SLUG, as well as cell adhesion molecules
including E-cadherin, have been known to confer resistance to anoikis [78]. Furthermore,
prostate cancer cells are able to alter their integrin expression profiles which leads to an
anoikis-resistant phenotype. Integrin αvβ3 in prostate as well as other cancers confers a
migratory phenotype and is overexpressed in the androgen-independent human prostate
cancer cells (PC3) [79]. Regarded as a characteristic consequence and a necessary
component to EMT, the processes of anoikis and EMT jointly contribute to the overall
properties of chemoresistance, immune evasion, and metastasis.

Therapeutic Resistance in CRPC
Author Manuscript

The clinical landscape of CRPC has evolved rapidly, particularly in the past half decade.
Patients today have FDA-approved options ranging from next-generation AR signaling
inhibitors abiraterone and enzalutamide, taxanes docetaxel and cabazitaxel, bone targeting
radiopharmaceutical radium-223, and dendritic cell vaccine sipuleucel-T, with additional
promising therapeutics in the developmental pipeline. Despite the explosion of options,
resistance to therapies in CRPC remains a critical area of unmet clinical need as evidenced
by the modest survival benefits offered by each of these treatments. On top of the unknowns
regarding optimal drug sequencing, the exact placement of drugs whose mechanisms of
action do not involve the AR or AR signaling axis, namely radium-223 and sipuleucel-T,
remains undetermined.

Author Manuscript
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The mechanisms contributing to the emergence of CRPC likely continue in the castrate state
as patients progress through additional lines of therapy. Instead of revisiting each of these
mechanisms, this section will highlight findings on resistance to therapies administered for
CRPC. Representative mechanisms are summarized in Table 1. In recent years, AR splice
variants (AR-V) have been uncovered as a novel mechanism via which AR signaling is
dynamically sustained in advanced lethal tumors. The AR-Vs are truncated forms of the AR
lacking the LBD, some of which are constitutively active and allow for the ligandindependent activation of AR target genes [92, 93]. The AR-V7, a clinically relevant variant
due to its ligand-independent activity, along with abundance, heightened expression in
CRPC tissues, and its detectable protein product has recently attracted interest as a potential
therapy-selecting biomarker [94–96] (Fig. 1(H)). Preclinical [97, 98] as well as clinical
evidence is suggestive of its role in resistance to novel AR-directed therapies abiraterone and
enzalutamide [84••] but not to taxane chemotherapies [83••]. The differential response of
AR-V7-positive patients to these two classes of therapy supports its use as a predictive
biomarker, yet important details on the precise role of AR-Vs still need to be elucidated.
Even after the emergence of CRPC, the tumor microenvironment remains a remarkable
contributor to tumor cell behavior at local and distal sites of invasion and metastasis. With a
higher likelihood of tumor dissemination in the CRPC state, each compartment within which
the tumor resides is a nurturing microenvironment—prostate, lymph node, bone, and so on.
Notably, since approximately 90% [99] of patients with advanced disease develop
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metastases to the bone, the leading cause of disease morbidity [100], there is great
momentum in characterizing the bone microenvironment dynamics and the targeting of bone
metastases in patients and in preclinical models towards overcoming therapeutic resistance.
While not strictly a resistance mechanism in and of itself, tumor establishment in the bone
niche is a known detriment to survival and quality of life [101, 102]. Interactions between
tumor cells and resident cells of the bone microenvironment contribute to the development
of bone metastases; tumor cells compete with hematopoietic stem cells (HSCs) for the
occupation of the osteoblastic niche. Particularly, metastasis to the bone was promoted if the
niche was altered in a way to eliminate HSCs from the bone microenvironment [103].
Clinically, denosumab, a human monoclonal antibody against receptor activator of NF-κB
(RANK), ligand has been shown to delay the risk of skeletal complications in those with
bone metastasis [104] as well as the development of bone metastatic disease in
nonmetastatic CRPC [105]. RANK ligand, an active player in the bone microenvironment
involved in normal bone turnover, has been shown to activate various transcription factors
regulating EMT, stem cell properties, neuroendocrine differentiation, and osteomimicry, as
well as promote bystander cell involvement in bone metastasis formation [106]. The
radiopharmaceutical radium-223 offers improvement in overall survival, further lending
support to the idea that the bone is a viable and important therapeutic target [107].
Resistance to Androgen Axis Inhibition/AR-Directed Therapies
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Enzalutamide is a second-generation antiandrogen initially approved in 2012 for patients
with mCRPC in the post-docetaxel setting, but its indication was later expanded in 2014 to
include chemotherapy-naïve men with mCRPC [108]. Enzalutamide binds the LBD of the
AR with high affinity, reducing AR nuclear translocation efficiency and disrupting binding
to androgen response elements (AREs) on DNA, and impairs the recruitment of AR
coactivators [109]. While the deployment of enzalutamide in clinical practice has
significantly altered the treatment paradigm of CRPC, resistance is inevitable as evidenced
by the modest improvement in overall survival. In addition, 25% of patients display primary
resistance to the drug [110]. The missense mutation F876L in the LBD is known to confer
resistance to enzalutamide by bestowing agonist properties [80••, 111], a common issue
encountered with first-generation antiandrogens. Further, apalutamide (previously known as
ARN-509), a newer second-generation antiandrogen, is also known to behave as an AR
agonist in the presence of this mutation. Interestingly, there is evidence to suggest that
mutants harboring F876L may respond to first-generation antiandrogens bicalutamide and
flutamide [81]. Such findings may warrant clinical investigation of rechallenging certain
patients with a previously failed agent. It also appears that GR induction, whose role is
appreciated in the progression to CRPC, is a bypass mechanism that leads to transcription of
AR-targeted genes and resistance to enzalutamide [112]. In the context of alternative AR
activation, there is evidence that the aforementioned NF-κB pathway, particularly the
upregulation of NF-κB2/p52, reactivates AR signaling through both full-length AR (AR-FL)
and AR-V [82].
Abiraterone acetate is a selective potent inhibitor of CYP17 [113] approved in 2011 for
mCRPC in the post-docetaxel setting, but with expanded indication in 2012 to include
chemotherapy-naïve men with CRPC [114]. The efficacy of abiraterone reflects the
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contribution of intratumoral and adrenal androgens in sustaining prostate cancer growth in
CRPC. As with enzalutamide, resistance to abiraterone is inevitable and up to a third of
patients display primary resistance [110]. Studies have revealed that several genes in
androgen biosynthesis pathways, including CYP17A1, the primary target of abiraterone, are
upregulated following treatment with abiraterone, representing an adaptation of tumors to
evade the effects of inhibition [98]. Further, CYP17 inhibition results in the accumulation of
upstream substrates, which may be utilized in alternative steroid biosynthesis pathways that
ultimately lead to DHT [115]. Given the relatively recent approvals of both enzalutamide
and abiraterone, much of their resistance mechanisms remain under exploration.
Resistance to Taxane Chemotherapies
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Recent advances in genomic cloning and phosphoproteomic profiling of advanced prostate
tumors have fueled great excitement in prostate cancer therapeutics towards the development
and implementation of personalized targeted therapies [85, 116••, 117]. Nevertheless, the
therapeutic impact of taxane-based first- and second-line chemotherapies (docetaxel and
cabazitaxel, respectively) on patient survival is still essential in the management of advanced
prostate cancer, both in hormonesensitive disease and CRPC [118••, 119••]. Docetaxel, first
approved for CRPC in 2004, was the only chemotherapeutic drug to improve overall survival
in patients with CRPC for the greater half of the following decade [120]. It is a microtubuletargeting (stabilizing) agent that binds to β-tubulin subunits, resulting in apoptosis and G2/M
cell cycle arrest [121, 122]. Microtubules are essential structures for facilitating AR
trafficking to the nucleus [86, 123], and the activity of docetaxel significantly depletes
nuclear AR [87]. In the CRPC setting, taxanes are an important therapeutic option for those
refractory to AR-targeting agents, but resistance develops after a median PSA response
duration of 7–8 months [14]. One well-documented mechanism of docetaxel resistance
involves the overexpression of ATP-binding cassette (ABC) transporter molecules such as Pglycoprotein contributing to increased drug efflux from the tumor cells [124]. Additionally,
structural changes in β-tubulin, such as the class III β-tubulin isoform, can affect docetaxel
binding and activity, diminishing docetaxel efficacy [88]. Notably, class III β-tubulin
expression is heightened as a result of androgen ablation [125] and is predictive of response
to docetaxel [126]. The former observation highlights the tumor’s ability to adapt to
therapeutic interventions. Furthermore, docetaxel resistance is also associated with EMT
induction, as evidenced by decreased E-cadherin expression and increased mesenchymal
markers [90], reaffirming the significance of tumor microenvironment phenotypic landscape
in therapeutic resistance.
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Given the relatively shorter period since its approval, resistance mechanisms to cabazitaxel,
a second-generation microtubule-stabilizing agent, are less understood. Mechanistically, it
was recently demonstrated that while cabazitaxel does not result in the depletion of nuclear
AR (as docetaxel), it reduces AR expression with the overall outcome of apoptosis [127].
Significantly enough, despite their similar targeting action against microtubules, the
mechanisms of docetaxel and cabazitaxel resistance (dissected so far) are not entirely
overlapping, implicating differential mechanisms of resistance. Thus, cabazitaxel has weaker
affinity for P-glycoprotein, and it is less susceptible to resistance via drug efflux compared
to docetaxel [91]. However, much like docetaxel, elevated class III β-tubulin and altered
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EMT markers do confer resistance to cabazitaxel treatment in advanced tumors [89]. In the
context of cross-resistance with antiandrogens, the therapeutic landscape becomes more
intriguing as the action of cabazitaxel as a second-line chemotherapy is unhindered in
enzalutamide-resistant prostate cancer, whereas docetaxel shows blunted efficacy [17].
Given that docetaxel is the standard first-line chemotherapy drug for CRPC and
cabazitaxel’s performance in this setting is unknown, questions regarding sequencing
remain, especially when coupled with implementation of AR-directed agents.
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Considering the potential impact of transient interconversions of EMT to its reverse process
mesenchymal-epithelial transition (MET) in the sequencing of taxane chemotherapy with
antiandrogens to impair lethal prostate cancer, recent efforts focus on profiling the EMT
phenotypic landscape towards building personalized signatures to predict therapeutic
response/resistance in patients with advanced disease. As discussed above, microtubuletargeting taxane chemotherapy offers a critical therapeutic avenue for those patients who
have failed AR-targeting strategies. The detection of AR-V7 in clinical specimens has not
been shown to predict resistance to taxanes [83••]; there is evidence that taxane
chemotherapy may even contribute to the reversion of theAR-V7phenotype [128]. Further,
recent work from our group provided exciting new evidence that in a preclinical model of
prostate tumor progression, cabazitaxel treatment induces prostate tumor cell
redifferentiation by reversing EMT to MET into the epithelial phenotype among therapyresistant prostate cancer cells [129]. Moreover, synergism of microtubule-targeting
chemotherapy, docetaxel, with the novel AR N-terminal domain (NTD) inhibitor
EPI-001/002, can navigate serial cycling of EMT to the reverse process of MET, supporting
the possibility of reprogramming the EMT profile in advanced disease, even in those tumors
harboring the AR variants [130]. Despite its temporal nature, the plasticity of EMT emerges
as an attractive target for resensitizing prostate tumors resistant to AR-directed therapies
and/or first- or second-line microtubule-targeting chemotherapies.

The Future of Clinical Management of Advanced CRPC
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Apparent from both the non-therapy-specific and therapy-specific mechanisms of resistance
in CRPC, tumor cells display remarkable adaptability. The clinical heterogeneity in disease
course is a reflection of the marked molecular heterogeneity observed in prostate cancer,
demanding a personalized approach to treatment [131]. Newer techniques of noninvasive
liquid biopsies including circulating tumor cells (CTCs) and circulating tumor DNA
(ctDNA) provide opportunities to examine tumor adaptations in real time and has profound
implications for precision medicine [132]. Significantly enough, liquid biopsies allow
prostate cancer to be followed temporally to identify resistant clones and driver mutations
that may account for therapeutic failure [116••]. As we become better acquainted with the
underlying molecular mechanisms that drive resistance and associated biomarkers, serial
biopsies are likely to provide additional insights into clinical decision-making.
Evidence from a series of combination approaches assessing the clinical benefit, including
abiraterone and enzalutamide, NCT01949337; Rad-223 and abiraterone, NCT02043678;
enzalutamide and docetaxel, NCT01565928, among many others, provides promise as to the
therapeutic sequencing of existing combination strategies. Particularly, with the heightened
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interest surrounding immunotherapies, combination strategies involving sipuleucel-T are
being considered as well for additive clinical benefits. For example, the potential approach
of combining sipuleucel-T and abiraterone, drugs with nonoverlapping toxicities, may
overcome the initial lag in objective clinical benefit often seen in sipuleucel-T monotherapy
[133]. In metastatic androgen-sensitive disease, the combination of docetaxel and ADT has
provided a significant survival advantage over ADT alone and is considered the standard of
care today [118••]. Considering that certain therapies together may have synergistic effects
preclinically [130], the shift towards strategic combination therapies for CRPC in the future
is certainly possible as well [134]. Preclinical and early clinical studies reveal promising
leads in novel therapeutic targets. A recent phase II study involving the PARP inhibitor
olaparib benefitted men with advanced CRPC harboring DNA repair mutations [135], which
occur at a frequency of 11.8% in patients with mCRPC [136]. These findings point at not
only a potential biomarker for treatment selection but also a therapeutic target in those who
have failed multiple lines of therapy. In the context of the tumor microenvironment, the
process of EMT is a potential target, given the relevance of EMT-to-MET cycling. TGF-β
inhibition necessitates a cautious undertaking due to its ubiquity and complex intersecting
signaling pathways but stands to open an alternative avenue to overcoming therapeutic
resistance to currently employed antiandrogen and taxane-based strategies [137], potentially
in the appropriately designed sequencing approach. Galunisertib (LY2157299), a small
molecule inhibitor targeting TGF-β receptor I, biologically impacting the EMT outcomes in
prostatic tumors is currently being investigated alongside enzalutamide (NCT02452008) in a
phase II study as well in preclinical models of advanced tumor progression to metastasis.

Conclusions
Author Manuscript
Author Manuscript

The seemingly simple reliance of prostate cells on androgens belies the complexities that
arise in advanced prostate cancer, all of which directly reflect the intricacies of the
mechanisms of resistance responsible for therapy failure in patients. Critically, further tumor
adaptations arise in the CRPC state driven by the specific selective pressures of nextgeneration AR-directed therapies and cytotoxic chemotherapies, many of which were
unknown until recently. Promisingly, however, resistance to these interventions may be
reversible by employing strategies such as EMT-to-MET cycling, yet our understanding of
how to optimize such synergism between preexisting and newer therapeutics is still limited.
Clinical management of advanced CRPC is challenging due to the diversity of resistant
clones, especially in those refractory to multiple lines of therapies. The future of prostate
cancer management in these patients will likely involve not only serial liquid biopsies to
assess disease state and probe for additional actionable targets but also strategic combination
strategies that induce reversal of the resistant phenotype. Ongoing studies on not only newer
therapeutic targets but also novel combination strategies will be crucial in controlling the
dynamic process of tumor clone evolution and prolonging survival in lethal prostate cancer.
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Fig. 1.
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Major mechanisms of therapeutic resistance to androgen axis-targeting therapies in prostate
cancer. A AR gene and mRNA amplifications to increase ligand sensitivity. B Utilization of
nonandrogen ligands such as estradiol and glucocorticoids. C AR activation via alternative
survival signaling pathways including PI3K/AKT, NF-κB, and RTKs. D AR coactivators can
enhance AR sensitivity to various alternative ligands. E Utilization of alternative ligand
synthesis pathways for conversion of adrenal androgen precursors. F Activation of TGF-β
signaling pathway in EMT-to-MET interconversions. G Overexpression of prosurvival
molecules such as Bcl-2 contributing to evasion of apoptosis activation. H AR splice variants
with ligand-independent activation promote AR transcriptional programs in the absence of
ligand
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Drug-specific mechanisms of resistance in CRPC therapy. Notably, non-drug-specific mechanisms driving the
development of hormone refractory disease continue to play a role in disease progression in CRPC
Drug-specific mechanism(s) of resistance
Enzalutamide

Abiraterone

Docetaxel

•

F876L missense mutation [80••, 81]

•

GR induction [82]

•

AR splice variants [83••]

•

CYP17A1 upregulation [84••]

•

Alternative ligand synthesis [85]

•

AR splice variants [83••]

•

Increased drug efflux [86]

Author Manuscript

•

Heightened class III β-tubulin expression [87]

•

EMT [88]

•

AR variants [89]

•

Heightened class III β-tubulin expression [90]

•

EMT [91]

•

Nuclear AR [91]

Sipuleucel-T

•

Undetermined

Radium-223

•

Undetermined

Apalutamide

•

F876L missense mutation [80••, 81]

Cabazitaxel
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